Home › NDC Lookup › Ingredients › Verapamil Hydrochloride › 00591-0343-01
⚪image loading
(from DailyMed)

Verapamil Hydrochloride 80 mg Tablet, Film Coated, 100-count — NDC 0591-0343-01 (Billing 00591-0343-01)

by Actavis Pharma, Inc. · 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

This is a package of 100 tablets of Verapamil Hydrochloride 80 mg Tablet, Film Coated from Actavis Pharma, Inc., marketed since Oct 1986 and currently FDA-listed; retail pharmacies pay about $0.0733 per tablet (NADAC). It is the main listing for this product, which comes in 5 package sizes.

NDC 00591-0343-01
🏷️ FDA NDC (as labeled) 0591-0343-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.0733 NADAC Per package$7.33 / 100 tablets Pack sizes5 compare ↓
Also priced by: Medicaid pays $0.1271/unit · Part D plans $0.1177/unit — full pricing hub ↓
Main listing for product 0591-0343 · Also comes in: 500 tablets 0591-0343-05 1000 tablets 0591-0343-10 44000 tablets 0591-0343-00 52692 tablets 0591-0343-77
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Verapamil Hydrochloride (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Jul 2, 2024 — Cross contamination with other products. (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0592-2024
Class III · Jul 2, 2024 — Cross contamination with other products. (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0593-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0591-0343-01
Product NDC 0591-0343
11-digit billing NDC 00591034301
NCPDP billing unit EA — each (per item)
SPL Set ID 97a44eae-e889-48d9-8973-631bb2a247fa
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1986-10-01
Dosage form TABLET, FILM COATED
Substance VERAPAMIL HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 34000030100305
GPI class Verapamil HCl
GCN Seq No 000566
GCN 02342
HICL code 000180
Ingredient (HICL) Verapamil Hcl
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A9
Therapeutic class — intermediate (HIC2) Calcium Antagonists
HIC3 code A9A
Therapeutic class — specific (HIC3) Calcium Channel Blocking Agents
AHFS code 24:04.04.24
AHFS class Class Iv Antiarrhythmics
FDB label name VERAPAMIL 80 MG TABLET
FDB brand name Verapamil Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 000566
  • GCN: 02342
  • GPI-14 (Medi-Span): 34000030100305
  • HICL (First Databank): 000180
  • AHFS class code: 24:04.04.24
Why two NDCs? The FDA registers this code as 0591-0343-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-0343-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name VERAPAMIL 80 MG TABLET Ingredient Verapamil Hcl
📖 What it is MedlinePlus · NLM

Verapamil is used to treat high blood pressure and to control angina (chest pain). The immediate-release tablets are also used alone or with other medications to prevent and treat irregular heartbeats. Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood ves...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Verapamil tablets treat angina, certain fast heart rhythms and high blood pressure. Extended-release forms are used for high blood pressure. The injectio...
  • Extended-release tablets are taken with food in the morning. The PM capsules are taken at bedtime. Swallow capsules whole, or sprinkle the entire contents on applesauce. Never crus...
  • How should I take my extended-release verapamil?
  • Constipation is the most common, along with headache, dizziness and ankle swelling. Tell your doctor if they bother you. Call right away for fainting, a very slow heartbeat, shortn...
📖 Read our full Verapamil guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
2
Nutrient depletion considerations

Verapamil may be associated with lower levels of 2 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Verapamil nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.073 $7.33 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1271 $12.71 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1177 $11.77 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.086 $0.051
▲ Up 44% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00591-0343-01 You're viewing this Main listing 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC $0.0733 / ea $7.33 1986-10-01 — Active
00591-0343-05 0591-0343-05 500 TABLET, FILM COATED in 1 BOTTLE, PLASTIC $0.0733 / ea $36.63 1986-10-01 — Active
00591-0343-10 0591-0343-10 1000 TABLET, FILM COATED in 1 BOTTLE, PLASTIC $0.0733 / ea $73.25 1986-10-01 — Active
00591-0343-00 0591-0343-00 44000 TABLET, FILM COATED in 1 BAG — — — — Active
00591-0343-77 0591-0343-77 52692 TABLET, FILM COATED in 1 CONTAINER — — — — Active

You're viewing the smallest of 5 pack sizes for this product.

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0733 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 89% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet, film coated in 1 bottle, plastic.
How does this package differ from NDC 00591-0343-05?
Both are Verapamil Hydrochloride 80 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 00591-0343-05 is the 500 tablets package.
What NDC number is used to bill for this package of Verapamil Hydrochloride 80 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Verapamil Hydrochloride 80 mgthis 00591-0343-01 Actavis 100 tablets $0.073 — Availability likely —
Verapamil Hydrochloride 80 mg 23155-0026-01 Heritage 100 tablets $0.073 AB Availability likely —
Verapamil Hydrochloride 80 mg 62135-0744-90 Chartwell 90 tablets $0.073 AB Availability likely —
Verapamil Hydrochloride 80 mg 42291-0854-01 AvKARE 100 tablets — AB FDA listed —
Verapamil Hydrochloride 80 mg 51407-0963-01 Golden 100 tablets — AB FDA listed —
Verapamil Hydrochloride 80 mg 68071-3434-00 NuCare 100 tablets — AB FDA listed —
Verapamil Hydrochloride 80 mg 72162-2232-01 Bryant 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1986
On the market since
Oct 1986
📍
2026
Currently FDA-listed
40 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Labeler code00591
First marketedOct 1986
Product typeDrug For Further Processing
Portfolio324 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
5.8K
Units reimbursed last 4 qtrs
557.4K
Gross reimbursed last 4 qtrs
$70.8K
Avg / prescription
$12.13
Avg / unit
$0.1271
Latest quarter Q1 2026
763Rx
Medicaid pays / ea
$0.1271
gross reimbursed
vs
NADAC / ea
$0.0733
acquisition cost
=
Spread
+$0.0538
+73% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
31% FFS 69% MCO
Fee-for-service · 1,833 Rx Managed care · 4,004 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 7,922 units · 101 per 100k residents WA Idaho: 2,607 units · 133 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 7,179 units · 125 per 100k residents MN Wisconsin: 11,801 units · 200 per 100k residents WI Michigan: 26,496 units · 264 per 100k residents MI New York: 34,175 units · 175 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 10,979 units · 259 per 100k residents OR Nevada: 9,394 units · 294 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 2,665 units · 83.1 per 100k residents IA Illinois: 20,915 units · 167 per 100k residents IL Indiana: 23,165 units · 338 per 100k residents IN Ohio: 26,869 units · 228 per 100k residents OH Pennsylvania: 36,003 units · 278 per 100k residents PA New Jersey: 16,505 units · 178 per 100k residents NJ Massachusetts: 18,012 units · 257 per 100k residents MA California: 79,421 units · 204 per 100k residents CA Utah: 1,338 units · 39.2 per 100k residents UT Colorado: 12,342 units · 210 per 100k residents CO Nebraska: no data reported NE Missouri: 4,525 units · 73.0 per 100k residents MO Kentucky: 14,651 units · 324 per 100k residents KY West Virginia: 10,355 units · 585 per 100k residents WV Virginia: 15,584 units · 179 per 100k residents VA Maryland: 8,942 units · 145 per 100k residents MD Connecticut: 8,355 units · 231 per 100k residents CT Rhode Island: 4,541 units · 415 per 100k residents RI Arizona: 17,060 units · 230 per 100k residents AZ New Mexico: 1,530 units · 72.4 per 100k residents NM Kansas: no data reported KS Arkansas: 2,010 units · 65.5 per 100k residents AR Tennessee: 7,373 units · 103 per 100k residents TN North Carolina: 14,106 units · 130 per 100k residents NC South Carolina: 1,939 units · 36.1 per 100k residents SC Delaware: 1,092 units · 106 per 100k residents DE Oklahoma: no data reported OK Louisiana: 8,180 units · 179 per 100k residents LA Mississippi: 1,435 units · 48.8 per 100k residents MS Alabama: 1,095 units · 21.4 per 100k residents AL Georgia: 9,874 units · 89.5 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 11,040 units · 36.2 per 100k residents TX Florida: 44,410 units · 196 per 100k residents FL
Units reimbursed · per 100k residents
21.4585
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 West Virginia 585 /100k
2 Rhode Island 415 /100k
3 Indiana 338 /100k
4 Kentucky 324 /100k
5 Nevada 294 /100k
6 Pennsylvania 278 /100k
7 Michigan 264 /100k
8 Oregon 259 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page00591-0343-01 5,837 Rx · $70,820
500 tablets00591-0343-05 716 Rx · $7,518
1000 tablets00591-0343-10 No Medicaid data
44000 tablets00591-0343-00 No Medicaid data
52692 tablets00591-0343-77 No Medicaid data
Drug total (last 4 qtrs): 6,553 Rx · 602,902 units · $78,338 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Actavis Pharma, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 4 other package presentations of this same product, including 500 tablets (00591-0343-05), 1000 tablets (00591-0343-10), 44000 tablets (00591-0343-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00575-6200-30 · Teva 00591-0345-01 · Actavis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.